Jefferies raises Gilead stock price target to $185 on acquisition
Jefferies raised Gilead Sciences' (GILD) price target to $185, citing the acquisition of PepStar Therapeutics' HCXT-2001 for $1.275B. The stock is near its 52-week high. Gilead's upcoming earnings on October 29 are anticipated. BofA Securities also raised its target, citing positive drug trial results.
How this was made
The 30-second read
Why it matters
The new price target and acquisition news provide a catalyst for short‑term buying, while the Phase 1 status of HCXT‑2001 suggests longer‑term risk.
Market read
Analyst price‑target raise combined with a sizable cash acquisition creates immediate upside potential for GILD.
What to watch
Potential regulatory hurdles for the oral IL‑23 candidate and competition from Johnson & Johnson's pipeline.
Background
Gilead Sciences (NASDAQ:GILD) is a leading antiviral and oncology company; recent analyst upgrades have focused on its expanding immunology portfolio.
Ticker impact
Jefferies raised its price target for Gilead Sciences to $185 and highlighted its $1.275 bn acquisition of PepStar Therapeutics' Phase 1 drug candidate.
upward pressure as investors price in the higher target and growth potential from the acquisition
The price target increase and disclosed cash deal represent fresh, material information that can move the stock immediately.
Market effects
Strengthens the biotech sector's outlook on oral immunology therapies.
Positive for US biotech equities and related ADRs.
Highlights continued M&A activity in the global pharma space.
Counterpoint
The acquisition may dilute Gilead's focus and the $1.275 bn cash outlay could strain balance sheet if the drug fails.
Key entities
- CompanyGilead Sciences
US‑listed biotech firm receiving a $1.275 bn acquisition.
- CompanyPepStar Therapeutics
Owner of the Phase 1 oral anti‑IL‑23 candidate HCXT‑2001.
